Please use this identifier to cite or link to this item:
Title: Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method
Contributor(s): Chen, Guo-Bo (author); Lee, Sang Hong  (author); Montgomery, Grant W (author); Wray, Naomi R (author); Visscher, Peter M (author); Gearry, Richard B (author); Lawrance, Ian C (author); Andrews, Jane M (author); Bampton, Peter (author); Mahy, Gillian (author); Bell, Sally (author); Walsh, Alissa (author); Connor, Susan (author); Sparrow, Miles (author); Bowdler, Lisa M (author); Simms, Lisa A (author); Krishnaprasad, Krupa (author); Radford-Smith, Graham L (author); Moser, Gerhard (author)
Publication Date: 2017-08-29
Open Access: Yes
DOI: 10.1186/s12881-017-0451-2
Handle Link:

Background: Predicting risk of disease from genotypes is being increasingly proposed for a variety of diagnostic and prognostic purposes. Genome-wide association studies (GWAS) have identified a large number of genome-wide significant susceptibility loci for Crohn’s disease (CD) and ulcerative colitis (UC), two subtypes of inflammatory bowel disease (IBD). Recent studies have demonstrated that including only loci that are significantly associated with disease in the prediction model has low predictive power and that power can substantially be improved using a polygenic approach.

Methods: We performed a comprehensive analysis of risk prediction models using large case-control cohorts genotyped for 909,763 GWAS SNPs or 123,437 SNPs on the custom designed Immunochip using four prediction methods (polygenic score, best linear genomic prediction, elastic-net regularization and a Bayesian mixture model). We used the area under the curve (AUC) to assess prediction performance for discovery populations with different sample sizes and number of SNPs within cross-validation.

Results: On average, the Bayesian mixture approach had the best prediction performance. Using cross-validation we found little differences in prediction performance between GWAS and Immunochip, despite the GWAS array providing a 10 times larger effective genome-wide coverage. The prediction performance using Immunochip is largely due to the power of the initial GWAS for its marker selection and its low cost that enabled larger sample sizes. The predictive ability of the genomic risk score based on Immunochip was replicated in external data, with AUC of 0.75 for CD and 0.70 for UC. CD patients with higher risk scores demonstrated clinical characteristics typically associated with a more severe disease course including ileal location and earlier age at diagnosis.

Conclusions: Our analyses demonstrate that the power of genomic risk prediction for IBD is mainly due to strongly associated SNPs with considerable effect sizes. Additional SNPs that are only tagged by high-density GWAS arrays and low or rare-variants over-represented in the high-density region on the Immunochip contribute little to prediction accuracy. Although a quantitative assessment of IBD risk for an individual is not currently possible, we show sufficient power of genomic risk scores to stratify IBD risk among individuals at diagnosis.

Publication Type: Journal Article
Grant Details: ARC/DP160102126
Source of Publication: BMC Medical Genetics, v.18, p. 1-11
Publisher: BioMed Central Ltd
Place of Publication: United Kingdom
ISSN: 1471-2350
Fields of Research (FoR) 2020: 310506 Gene mapping
Socio-Economic Objective (SEO) 2020: 280102 Expanding knowledge in the biological sciences
Peer Reviewed: Yes
HERDC Category Description: C1 Refereed Article in a Scholarly Journal
Appears in Collections:Journal Article
School of Environmental and Rural Science

Files in This Item:
2 files
File Description SizeFormat 
openpublished/PerformanceLee2017JournalArticle.pdfPublished version712.47 kBAdobe PDF
Download Adobe
Show full item record


checked on May 13, 2023

Page view(s)

checked on Mar 8, 2023


checked on Mar 8, 2023
Google Media

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons